At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,102 enrolled
Drug / intervention
Theraflex, BAY 874017drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex® Treatment to Evaluate Changes in Pain, Functions in Daily Living, and Quality of Life for an Observation Period up to 64 Weeks
In Brief
An observational study evaluating Theraflex, BAY 874017 for Osteoarthritis. Completed, enrolled 1,102 participants across 2 sites.
Detailed Summary
The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient satisfaction with treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartNov 2017
Primary CompletionMar 2020
Study CompletionJul 2020
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartNov 20, 2017
Primary CompletionMar 18, 2020
Study CompletionJul 13, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.7 years ago
Interventions
Theraflex, BAY 874017drug
The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day